

Vermont Blue Rx Group C

Effective January 2023

Understanding the MedicalRx List

Unless otherwise noted this medical drug list applies to Commercial lines of business.

Drugs on this list may require prior authorization; look for the PA in the notes next to the drug name.

This list is not based upon the terms of your particular benefit plan. Each benefit plan contains its own specific provisions for coverage and exclusions. Not all benefits that are determined to be medically necessary will be covered benefits under the terms of your benefit plan. Check your plan documents.

Absence from this list does not imply non-coverage; drugs in other categories or drug classes may be eligible per the benefit plan.

Unless stated otherwise within the plan documents coverage is predicated on the medication being used within an FDA-approved dosing regimen as stated within the FDA product labeling.

Check your plan documents for benefit coverage information.

Status: P = Preferred NP = Non Preferred C= Covered

Notes: * = Rx guidelines apply ** = PA consistent with FDA label ***= Clinical PA

Drug Name	Drug Status	Notes
Hormonal Agents — Contraceptives		
Implanon	C	
Kyleena	C	
Liletta	C	
Mirena	C	
Nexplanon	C	
Paragard	C	
Skyla	C	
Hemophilia Agents		
Advate	P	
Adynovate	P	

Vermont Blue Rx Group C

Drug Name	Drug Status	Notes
Afstyla	P	
Alphanate	P	
Eloctate	C	
Esperoct	P	
Helixate FS	C	
Hemophil M	C	
Humate-P	C	
Hemlibra	C	
Jivi	P	
Koate	P	
Kogenate FS	P	
Kovaltry	P	
Monoclata-P	C	
Novoeight	P	
Nuwiq	P	
Recombinant	P	
Wilate	C	
Xyntha	P	
Xyntha Solofuse	P	
Immunomodulators		
Cimzia	C	
Entyvio	P	
Orencia IV	P	
Simponi Aria	P	
Stelara IV	P	
Stelara SubQ	P	
Monoclonal Antibodies/Antineoplastics – bevacizumab products		
Avastin	C	
Mvasi	C	

Vermont Blue Rx Group C

Drug Name	Drug Status	Notes
Zirabev	P	
Long acting G-CSF – pegfilgrastim		
Fulphila	P	
Neulasta	P	
Neulasta Onpro	P	
Nyvepria	C	
Udenyca	P	
Ziextenzo	C	
Monoclonal Antibodies – rituximab products		
Rituxan	C	
Rituxan Hycela	C	
Ruxience	P	
Truxima	C	
Riabni	P	
Immunological Modifiers – infliximab products		
Avsola	P	
Inflectra	P	
Infliximab	P	
Remicade	P	
Erythropoiesis-stimulating agents (ESA)		
Aranesp	P	
Mircera	C	
Procrit	P	
Retacrit	P	
HER2 Inhibitors – trastuzumab products		
Herceptin	C	
Herceptin Hylecta	C	

Vermont Blue Rx Group C

Drug Name	Drug Status	Notes
Herzuma	C	
Kanjinti	C	
Ogivri	C	
Ontruzant	C	
Trazimera	P	
HER2 Inhibitors – other		
Perjeta	C	
Phesgo	P	
Hormone Replacement		
Makena	P	
Gonadotropin-releasing hormone agonists		
Fensolvi	P	
Lupron Ped	C	
Supprelin LA	P	
Triptodur	P	
Somatostatin Agonists		
Sandostatin LAR	C	
Somatuline Depot	P	
Lanreotide	C	
Colony-stimulating Factor		
Nplate	C	
Monoclonal Antibodies – NMOSD Agents		
Enspryng	C	
Soliris	C	
Ultomiris	C	
Uplizna	C	
VEGF		

Vermont Blue Rx Group C

Drug Name	Drug Status	Notes
Beovu	C	
Eylea	P	
Lucentis	C	
Cimerli	P	
Byooviz	C	
Spinal Muscular Atrophy		
Spinraza	C	
Zolgensma	C	
Multiple Sclerosis		
Aubagio	C	
Avonex	C	
Betaseron	C	
Extavia	C	
Gilenya	C	
Lemtrada	C	
Kesimpta	C	
Mavenclad	C	
Mayzent	C	
Ocrevus	C	
Plegridy	C	
Rebif	C	
Zeposia	C	
Tysabri	C	
Asthma Biologics		
Cinqair	C	
Fasenra	C	
Nucala	C	

Vermont Blue Rx Group C

Drug Name	Drug Status	Notes
Xolair	C	
Immunological Angets - IVIG SubQ		
Cuvitru	C	
Cutaquig	C	
Hizentra	C	
Hyqvia	C	
Xembify	C	
Opioid Partial Agonist		
Sublocade	C	
Myasthenia Gravis		
Vyvgart	C	
HIV		
Cabenuva	C	
Alpha-1 Proteinase Inhibitors		
Aralast NP	C	
Glassia	C	
Prolastin-C	C	
Zemaira	C	
Intravenous Irons		
Monoferic	C	
Injectafer	C	
Feraheme	C	